Notice: This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NVUS vs. COCP, FBRX, PULM, IBIO, BOLT, ACXP, PIRS, MIRA, NRBO, and GLYCShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include Cocrystal Pharma (COCP), Forte Biosciences (FBRX), Pulmatrix (PULM), iBio (IBIO), Bolt Biotherapeutics (BOLT), Acurx Pharmaceuticals (ACXP), Pieris Pharmaceuticals (PIRS), MIRA Pharmaceuticals (MIRA), NeuroBo Pharmaceuticals (NRBO), and GlycoMimetics (GLYC). These companies are all part of the "medical" sector. Novus Therapeutics vs. Cocrystal Pharma Forte Biosciences Pulmatrix iBio Bolt Biotherapeutics Acurx Pharmaceuticals Pieris Pharmaceuticals MIRA Pharmaceuticals NeuroBo Pharmaceuticals GlycoMimetics Cocrystal Pharma (NASDAQ:COCP) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking. Do analysts recommend COCP or NVUS? Cocrystal Pharma presently has a consensus target price of $7.00, suggesting a potential upside of 224.07%. Given Cocrystal Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Cocrystal Pharma is more favorable than Novus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Novus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in COCP or NVUS? Novus Therapeutics received 229 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 76.67% of users gave Cocrystal Pharma an outperform vote while only 66.84% of users gave Novus Therapeutics an outperform vote. CompanyUnderperformOutperformCocrystal PharmaOutperform Votes2376.67% Underperform Votes723.33% Novus TherapeuticsOutperform Votes25266.84% Underperform Votes12533.16% Which has more risk & volatility, COCP or NVUS? Cocrystal Pharma has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Is COCP or NVUS more profitable? Cocrystal Pharma's return on equity of -94.62% beat Novus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cocrystal PharmaN/A -94.62% -78.24% Novus Therapeutics N/A -133.49%-30.52% Does the media favor COCP or NVUS? In the previous week, Cocrystal Pharma had 4 more articles in the media than Novus Therapeutics. MarketBeat recorded 4 mentions for Cocrystal Pharma and 0 mentions for Novus Therapeutics. Cocrystal Pharma's average media sentiment score of 0.76 beat Novus Therapeutics' score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the media. Company Overall Sentiment Cocrystal Pharma Positive Novus Therapeutics Neutral Do insiders and institutionals hold more shares of COCP or NVUS? 6.7% of Cocrystal Pharma shares are owned by institutional investors. 25.6% of Cocrystal Pharma shares are owned by insiders. Comparatively, 2.2% of Novus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, COCP or NVUS? Cocrystal Pharma is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCocrystal PharmaN/AN/A-$17.98M-$1.85-1.17Novus TherapeuticsN/AN/A-$16.01M-$21.58-0.18 SummaryCocrystal Pharma beats Novus Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.53M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-0.175.5095.1214.22Price / SalesN/A375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book0.2910.276.976.37Net Income-$16.01M$153.22M$118.73M$225.56M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$3.85-0.8%N/A+203.1%$5.53MN/A-0.177High Trading VolumeCOCPCocrystal Pharma3.0393 of 5 stars$2.16+4.9%$7.00+224.1%+25.6%$21.97MN/A-1.1710FBRXForte Biosciences3.6486 of 5 stars$14.80+9.2%$23.58+59.3%+69,372.9%$21.61MN/A-0.685Analyst RevisionNews CoverageGap DownHigh Trading VolumePULMPulmatrix0.2614 of 5 stars$5.92+5.3%N/A+210.5%$21.61M$7.30M-2.2820Analyst ForecastGap UpIBIOiBio1.3721 of 5 stars$2.36+7.8%$4.30+82.2%N/A$21.59M$220,000.000.00100Positive NewsBOLTBolt Biotherapeutics3.4321 of 5 stars$0.56-1.8%$3.50+525.0%-37.7%$21.43M$7.88M0.00100ACXPAcurx Pharmaceuticals2.3921 of 5 stars$1.26-9.4%$12.00+852.4%-61.6%$21.28MN/A0.003Short Interest ↓Analyst RevisionNews CoverageGap UpHigh Trading VolumePIRSPieris Pharmaceuticals1.6396 of 5 stars$15.93-0.5%N/A-10.4%$21.03M$42.81M-1.32140Analyst UpgradeNews CoverageGap DownMIRAMIRA Pharmaceuticals1.6713 of 5 stars$1.27flat$14.00+1,006.7%-72.8%$20.95MN/A0.002NRBONeuroBo Pharmaceuticals2.331 of 5 stars$2.40flat$10.00+316.7%-31.1%$20.69MN/A0.008Gap DownGLYCGlycoMimetics3.442 of 5 stars$0.31-5.5%$10.00+3,106.2%-78.4%$20.11M$10,000.000.0050Gap Down Related Companies and Tools Related Companies COCP Alternatives FBRX Alternatives PULM Alternatives IBIO Alternatives BOLT Alternatives ACXP Alternatives PIRS Alternatives MIRA Alternatives NRBO Alternatives GLYC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NVUS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVUS Stock Alerts